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and arthritis of the hand or wrist (34.1%) were the most com-
monly reported. Compared with other variables, age, arthritis,
and depressive symptoms were highly associated with the SF-36
physical domains. Depressive symptoms had the strongest asso-
ciation with each of the four SF-36 mental domains. Among the
chronic conditions, the adverse impact of having difﬁculty in
controlling urination, a relatively neglected condition, was only
second to depressive symptoms in its negative relationship with
vitality, social-functioning, and mental health. CONCLUSION:
Chronic conditions were commonly reported among the older
adults. The unique associations found between chronic condi-
tions and domains of health status demonstrate the importance
of examining the burden of these conditions in terms of func-
tioning and well-being.
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OBJECTIVES: To measure over-the-counter (OTC) drug misuse
in the elderly and study its relationship with health-related
quality of life (HRQOL). In addition, adverse drug events
(ADEs) due to OTC misuse and its relationship to HRQOL were
examined. METHODS: A questionnaire will be administered to
a sample of elderly patients, aged 65 and above, selected ran-
domly from those attending community wellness programs in the
Houston area. Information on OTC drug use/misuse, ADEs,
HRQOL and demographic data were obtained using a combi-
nation of self-administered questionnaire and personal interview
technique. HRQOL was measured using the SF-12v2 scale and
analyzed using the SAS statistical package at a priori set signiﬁ-
cance level of 0.05. RESULTS: A total of 157 surveys were 
collected resulting in a correct response rate of 66.53% from
four senior retirement centers. There were slightly more males
(56.21%) and Hispanic participants (67.55%) with a median age
of 74 years. Misuse occurred in 18% of the respondents and
ADEs in 23%. The mean physical (PCS) and mental (MCS) com-
ponent scores of the SF-12 scale were similar for the elderly (PCS
= 52. 53 ± 8.35, MCS = 53.99 ± 6.91). There was no signiﬁcant
difference in the occurrence of ADEs between those who did or
did not misuse OTC products. Although there was no signiﬁcant
difference in HRQOL in those who did or did not misuse OTC
products, there was a signiﬁcant difference in HRQOL between
those who experienced ADEs (PCS = 49.50 ± 6.86) and those
who did not (PCS 53.49 ± 8.21). However, the signiﬁcant effect
was predominately associated with the PCS and its domains
namely, physical functioning, role physical, and general health.
CONCLUSIONS: Understanding trends in OTC drug use and
misuse will help in devising methods to prevent ADEs and addi-
tionally improve HRQOL.
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OBJECTIVES: The primary purpose of this study is to compare
two widely used generic quality of life measures, SF-12 and EQ-
5D, in differentiating between appropriate and inappropriate
prescription medication users in an elderly cohort. METHODS:
Participants 65 years or older were taken from the Medical
Expenditure Panel Survey (MEPS) panel ﬁve from January, 2000
to December, 2001. A longitudinal retrospective cohort study
was conducted. Potential appropriate and inappropriate pre-
scription medication users were identiﬁed based on updated
Beers criteria list identifying inappropriate drug use in the elderly
(Fick, 2003). National Drug Code numbers were used to iden-
tify potential inappropriate prescription drug use. The dependent
variable, quality of life was measured using self-report versions
of SF-12 (mental health, MCS, physical health, PCS and general
health score) and EQ-5D (index, EQ-5DIndex and visual ana-
logue scale score, EQ-5DVAS). Using OLS regression, health
status scores were regressed on age, gender, prescription number
and health status in the previous year. RESULTS: Of the 716 par-
ticipants aged 65 years in the dataset, 455 were identiﬁed to have
appropriate drug use in 2000. Of these, 381 and 74 met the cri-
teria for appropriate and inappropriate drug use, respectively, in
2001. Appropriate prescription drug users had higher health
status scores than inappropriate users for PCS, and EQ-5D
(index and VAS scores), at the 0.05 level. Regression analysis
reported signiﬁcant model for PCS (Adjusted R2 = 0.3032, p <
0.0001); with signiﬁcant beta weights for prescription number,
prior health status, age and inappropriate drug use (p < 0.05).
CONCLUSION: Aging population is at greater risk of adverse
health events which can signiﬁcantly affect their quality of life.
Generic measures showed higher quality of life scores for indi-
viduals with appropriate drug use over those without. Prospec-
tive studies investigating inappropriate drug use, disease speciﬁc
quality of life measures, in addition to the impact on cost are
warranted.
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OBJECTIVES: The long-term cost-effectiveness of newer treat-
ments for BPH, including transuretheral microwave thermother-
apy (TUMT) and combination medical therapy, has not been
sufﬁciently studied against existing alternatives. This study 
compared the cost-utility and cost-consequences of watchful
waiting (WW), alpha-blockers (AB), 5-alpha-reductase inhibitors
(5ARI), their combination, TUMT, and transurethral prostatec-
tomy (TURP) in men with moderate to severe BPH symptoms.
METHODS: A Markov model was constructed to estimate the
clinical consequences, costs, and incremental cost per quality-
adjusted life year (QALY) gained. Clinical consequences included
progression to TURP, adverse events, and corresponding QALYs.
Treatment costs were estimated from an insurance claims 
database and Medicare fee schedules. Treatment response and
adverse event estimates were derived from published literature.
Analyses considered a 20-year time frame, societal perspective,
different age cohorts, symptom levels, and possible treatment
switching. Cost and effectiveness were discounted at 3% per
year. RESULTS: AB was cost-effective for treating moderate
symptoms using the threshold of $50,000/QALY for most
cohorts ($15,000–26,000 per QALY relative to WW). TURP was
the most cost-effective treatment for severe symptoms relative 
to WW ($4,000–17,000 per QALY). 5ARI and combination
therapy were dominated by alternatives due to annual pharma-
ceutical costs. The cost/QALY increased with age for TUMT and
TURP and was stable for AB. Results were robust to costs, but
sensitive to probabilities, utility weights, and life expectancy.
Acceptability curves showed consistent trends for the alternatives
most likely to be cost-effective. Preliminary expected value of
perfect information (EVPI) analysis suggests additional informa-
